Table of contents
- Brexit
- Amsterdam prepares to host European Medicines Agency post-Brexit
- EU publishes guidance for pharmaceutical companies to prepare for Brexit
- UK pharmaceutical industry moving jobs overseas to prepare for Brexit
- Manufacture, marketing and sale
- EMA revised strategy on measuring the impact of pharmacovigilance activities
- 2016/17 Pharmacovigilance inspection report identifies 150 major findings
- Research and development
- EU initiative on co-operation against vaccine-preventable diseases
- Intellectual property
More sections of this document available when you sign-in to Lexis+ or register for a free trial.
Article summary
This week’s edition of Life Sciences highlights includes analysis of the decision to relocate the European Medicines Agency (EMA) from London to Amsterdam post Brexit, the EMA’s latest guidance for pharmaceutical companies to prepare for Brexit and a report on the EMA’s revised strategy on measuring the impact of pharmacovigilance activities.
To continue reading this news article, as well as thousands of others like it, sign in with LexisNexis or register for a free trial
Access this content for free with a 7 day trial of LexisNexis and benefit from:
- Instant clarification on points of law
- Smart search
- Workflow tools
- 42 practice areas
Get your quote today and take step closer to being able to benefit from:
- Instant clarification on points of law
- Smart search
- Workflow tools
- 36 practice areas
Get a quote for Lexis+
* denotes a required field
CONTACT US
